Imugene Ltd (ASX: IMU) Share Price and News

Price

$0.024

Movement

0.00 (0.0)

as at 2 May - Closed (20 mins delayed)

52 Week Range

$0.023 - $0.086

 
1 Year Return

-71.76%

Imugene Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $179.21 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 7.58 billion
Earnings per share -0.018
Dividend per share N/A
Year To Date Return -35.14%
Earnings Yield N/A
Franking -
Share Price

$0.024

Day Change

0.00 (0.0)

52 Week Range

$0.023 - $0.086

Yesterday's Close

$0.024

Today's Open

$0.024

Days Range

$0.023 - $0.024

Volume

11,265,533

Avg. Volume (1 month)

20,458,928

Turnover

$264,079

as at 2 May - Closed

Imugene Ltd (ASX: IMU)
Latest News

Man pointing at a blue rising share price graph.
Share Gainers

Why Collins Foods, Healius, Imugene, and Link shares are climbing today

These ASX shares are having a stronger day than most on Tuesday.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Avita Medical, Imugene, Pantoro, and Tietto shares are pushing higher

These ASX shares are having a good finish to the week. But why?

Read more »

Three businesspeople leap high with the CBD in the background.
Healthcare Shares

Imugene share price jumps 34% on 'major milestone': What is it?

The healthcare stock is roaring higher again on Friday. But what's getting investors excited?

Read more »

A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
Share Gainers

Why Imugene, Lottery Corp, Orica, and Sayona Mining shares are storming higher

These ASX shares are catching the eye on Thursday. But why?

Read more »

surprised asx investor appearing incredulous at hearing asx share price
Healthcare Shares

Guess which ASX All Ords stock is up 60% in just two days

This ASX share is smashing the market this week. But why?

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Imugene, Mayne Pharma, Westpac, and Wildcat shares are storming higher

These ASX shares are starting the week strongly.

Read more »

Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
Healthcare Shares

The Imugene share price just leapt 10%. Here's why the ASX biotech stock is rocketing

Imugene shares are rising fast on Monday.

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Share Gainers

Why Boss Energy, Imugene, Polynovo, and TechnologyOne shares are racing higher

These ASX shares are having a positive start to the week.

Read more »

Top ten gold trophy.
Share Market News

Here are the top 10 ASX 200 shares today

The ASX 200 once again managed a tentative gain this Tuesday.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Beaten-up ASX 200 evictee Imugene stock surges on patent news

This biotech is having a strong session on Tuesday.

Read more »

Top ten gold trophy.
Share Market News

Here are the top 10 ASX 200 shares today

The markets went backwards today, but we still had some gains amongst our top shares.

Read more »

Frequently Asked Questions

IMU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
1st May 2025 2025-05-01T11:59:00 Letter to ShareholdersYesNo11:59am7184k
30th Apr 2025 2025-04-30T08:47:48 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo8:47am13645k
14th Apr 2025 2025-04-14T16:45:05 Application for quotation of securities - IMUYesNo4:45pm818k
11th Apr 2025 2025-04-11T16:55:33 Notification of cessation of securities - IMUYesNo4:55pm616k
11th Apr 2025 2025-04-11T16:50:43 Notification regarding unquoted securities - IMUYesNo4:50pm818k
10th Apr 2025 2025-04-10T09:35:29 Investor Update & FAQ WebinarYesNo9:35am2146k
3rd Apr 2025 2025-04-03T08:51:08 1st dose level cleared IV combination arm onCARlytics trialYesNo8:51am3174k
19th Mar 2025 2025-03-19T09:02:47 Azer-cel Granted FDA Fast Track Designation in Blood CancerYesNo9:02am3171k
13th Mar 2025 2025-03-13T17:51:17 Application for quotation of securities - IMUYesNo5:51pm819k
7th Mar 2025 2025-03-07T17:01:18 S&P DJI Announces March 2025 Quarterly RebalanceYesNo5:01pm8179k

About Imugene Ltd

Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

IMU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 May 2025 $0.02 $0.00 0.00% 11,265,533 $0.02 $0.02 $0.02
01 May 2025 $0.02 $0.00 0.00% 8,572,400 $0.02 $0.03 $0.02
30 Apr 2025 $0.02 $0.00 0.00% 28,700,582 $0.02 $0.03 $0.02
29 Apr 2025 $0.03 $0.00 0.00% 17,181,883 $0.03 $0.03 $0.02
28 Apr 2025 $0.03 $0.00 0.00% 4,329,344 $0.03 $0.03 $0.03
24 Apr 2025 $0.03 $0.00 0.00% 11,658,037 $0.03 $0.03 $0.03
23 Apr 2025 $0.03 $0.00 0.00% 28,590,644 $0.02 $0.03 $0.02
22 Apr 2025 $0.02 $0.00 0.00% 8,328,723 $0.02 $0.02 $0.02
17 Apr 2025 $0.02 $0.00 0.00% 34,372,350 $0.02 $0.03 $0.02
16 Apr 2025 $0.03 $0.00 0.00% 14,449,766 $0.03 $0.03 $0.03
15 Apr 2025 $0.03 $0.00 0.00% 18,432,396 $0.03 $0.03 $0.03
14 Apr 2025 $0.03 $0.00 0.00% 7,725,833 $0.03 $0.03 $0.03
11 Apr 2025 $0.02 $0.00 0.00% 10,760,349 $0.02 $0.03 $0.02
10 Apr 2025 $0.02 $0.00 0.00% 16,098,086 $0.03 $0.03 $0.02
09 Apr 2025 $0.02 $0.00 0.00% 31,660,115 $0.03 $0.03 $0.02
08 Apr 2025 $0.03 $0.00 0.00% 18,642,455 $0.03 $0.03 $0.03
07 Apr 2025 $0.02 $0.00 0.00% 35,373,653 $0.02 $0.03 $0.02
04 Apr 2025 $0.03 $0.00 0.00% 38,080,420 $0.03 $0.03 $0.03
03 Apr 2025 $0.03 $0.00 0.00% 27,485,660 $0.03 $0.03 $0.03

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
14 Feb 2025 Leslie (Mi Ok) Chong Exercise 4,828,125 $207,609
Conversion of securities. 1,25,53,125 Performance Rights Award
14 Feb 2025 Leslie (Mi Ok) Chong Issued 4,828,125 $207,609
Conversion of securities.
14 Feb 2025 Leslie (Mi Ok) Chong Issued 19,312,500 $830,437
Employee Share Ownership Plan. 31,865,625 - Performance Rights Award
14 Feb 2025 Paul Hopper Exercise 894,094 $38,446
Conversion of securities. 20,32,031 Performance Rights Award
14 Feb 2025 Paul Hopper Issued 3,576,375 $153,784
Employee Share Ownership Plan. 5,608,406 - Performance Rights Award
14 Feb 2025 Paul Hopper Issued 894,094 $38,446
Conversion of securities.
14 Feb 2025 Lesley Russell Issued 2,000,000 $86,000
Employee Share Ownership Plan. 2,750,000 - Restricted Stock Units (RSUs)
14 Feb 2025 Jakob Dupont Issued 2,000,000 $86,000
Employee Share Ownership Plan. 2,750,000 - Restricted Stock Units
14 Feb 2025 Kim Drapkin Issued 2,000,000 $86,000
Employee Share Ownership Plan. 2,750,000 Restricted Stock Units
01 Jul 2024 Kim Drapkin Exercise 250,000 $13,750
Conversion of securities. 750,000 - Restricted Stock Units
01 Jul 2024 Kim Drapkin Issued 250,000 $13,750
Conversion of securities. As per announcement on 08-07-2024
01 Jul 2024 Jens Eckstein Exercise 250,000 $13,750
Conversion of securities. 750,000 RSU
01 Jul 2024 Jens Eckstein Issued 250,000 $13,750
Conversion of securities.
01 Jul 2024 Jakob Dupont Issued 250,000 $13,750
Conversion of securities.
01 Jul 2024 Jakob Dupont Exercise 250,000 $13,750
Conversion of securities. 750,000 - Restricted Stock Units
01 Jul 2024 Lesley Russell Issued 250,000 $13,750
Conversion of securities.
01 Jul 2024 Lesley Russell Exercise 250,000 $13,750
Conversion of securities. 750,000 - Restricted Stock Units
01 Jul 2024 Paul Hopper Issued 975,375 $53,645
Conversion of securities.
01 Jul 2024 Paul Hopper Exercise 975,375 $53,645
Conversion of securities. 2,926,125 PERFORMANCE RIGHTS AWARD
01 Jul 2024 Leslie (Mi Ok) Chong Exercise 5,793,750 $318,656
Conversion of securities. 17,381,250 RIGHTS
01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
As advised by the company. Transfer from direct to indirect holding
01 Jul 2024 Leslie (Mi Ok) Chong Buy 5,793,750 $318,656
Conversion of securities.
01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
As advised by the company. Transfer from direct to indirect holding

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
Ms Chong joined the Group from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in leading clinical and department development in oncology. In November 2016, Former directorships in last three years - Cure Brain Cancer Foundation (non-profit organisation), until 11 April 2023.
Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered therapeutic areas with emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Former directorships in last three years include Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.
Dr Lesley Russell Non-Executive Director Apr 2019
Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology and has had new drug approvals with FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships - Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016. Dr Russell is member of Risk Committee.
Dr Jakob Dupont Non-Executive Director Sep 2022
Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and preclinical programs. Other current directorships include Pyxis Oncology (NASDAQ: PYXS); Avenzo Therapeutics and Flagship Pioneering (Scientific Advisory Board). Former directorships in last three years - Apexigen (NASDAQ: APGN) until August 2023. Dr Dupont is member of the Risk Committee.
Ms Kim Drapkin Non-Executive Director Jun 2023
Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process culminating in a reverse merger with LENZ Therapeutics. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a role in building Jounce's financial infrastructure. Prior to joining Jounce, Ms Drapkin owned a financial consulting firm where she served as the interim chief financial officer for early stage biotechnology companies. Previously, Ms Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms Drapkin spent ten years in roles of increasing responsibility within the finance organisation at Millennium Pharmaceuticals. Ms Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Other current directorships are held with Acumen Pharmaceuticals (NASDAQ: ABOS); LENZ Therapuetics (NASDAQ: LENZ). Former directorships in last three years - Yumanity Therapeutics (NASDAQ: YMTX); Proteostasis Therapeutics (NASDAQ: PTI). She is chair of risk committee.
Mr Darren Keamy Chief Financial OfficerCompany Secretary Mar 2025
-
Monil Shah Chief Business Officer
-
Mike Tonroe Chief Financial Officer
-
Darren Keamy Chief Financial OfficerCompany Secretary
-
Paul Woodard Chief Medical Officer
-
Bradley Glover Chief Operating Officer
-
Nicholas Ede Chief Technology Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Paul Hopper 409,071,906 5.57%
JP Morgan 283,996,697 3.86%
Citicorp Nominees Pty Limited 266,813,810 3.63%
Mann Family 265,582,609 3.61%
HSBC Custody Nominees (Australia) Limited i 213,532,203 2.91%
Dr Nicolas Smith 118,000,000 1.61%
Netwealth Investments Limited <Wrap Ser Vices A/C> 85,488,611 1.16%
Mi Ok Chong 78,416,666 1.07%
BNP Paribas Noms Pty Ltd 70,407,583 0.96%
National Nominees Pty Ltd 60,113,645 0.82%
UBS Nominees Pty Ltd 50,328,041 0.68%
BNP Paribas Noms Pty Ltd <Ib Au Noms Retail Client> 48,979,324 0.67%
HSBC Custody Nominees (Australia) Limited ii 29,079,510 0.40%
Mr Phillip Wood 25,480,000 0.35%
Sve Capital Pty Ltd <Strategic Vision Unit A/C> 23,000,000 0.31%
Dr Yuman Fong 22,379,032 0.30%
Dr Jen Eckstein 20,738,095 0.28%
Dr Lesley Russell 20,238,095 0.28%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 20,230,709 0.28%
Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin <Pappin Super Fund A/C> 20,000,000 0.27%
Jem Investment Fund Holdings Pty Ltd <Jem Invest Fund Family A/C> 20,000,000 0.27%

Profile

since

Note